SenzaGen AB engages in the development of in vitro test methods for prediction of chemical and protein sensitizers. It offers services for assessment of sensitizers for industry and regulatory purposes, using its proprietary technology called GARD (Genomic Allergen Rapid Detection). It serves clients in cosmetic, chemical, pharmaceutical, and food industries. The company was founded by Malin Marie Lindstedt and Carl Arne Krister Borrebaeck on August 18, 2010 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company